A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors

Up to approximately 192 participants may be assigned to study intervention in the study across approximately 30 sites globally.

An Open-label, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MEDI9253, a Recombinant Newcastle Disease Virus Encoding Interleukin-12, in Combination With Durvalumab in Participants With Select Advanced/Metastatic Solid Tumors

Study D7880C00001 is a first-in-human (FIH), Phase 1, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of MEDI9253 in combination with durvalumab in adult participants with select advanced/metastatic solid tumors.

A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors

Recruitment

Summary

Participation Requirements

Description

Tracking Information